Abstract
Fructose-1,6-bisphosphatase 1 (FBP1) is a rate-limiting enzyme in gluconeogenesis. Recently, the catalytic activity-independent function of FBP1, hypoxia-induced factor (HIF) repression in the nucleus, was identified. The aim of the present study was to investigate the association between FBP1 and hypoxia-related gene expression in clear cell renal cell carcinoma (ccRCC). The protein expression levels of FBP1, HIF-1α, HIF-2α, erythropoietin (EPO) and carbonic anhydrase IX (CA9) were assessed by immunohistochemical staining of ccRCC paraffin blocks from 123 patients using the tissue microarray technique. The expression level of FBP1 was then correlated with various clinicopathological factors, and the protein expression levels of HIF-1α, HIF-2α, EPO and CA9. Clinicopathological factors, including age, gender, T stage and Fuhrman grade, were not significantly different between patients with low and high FBP1 expression in ccRCC (P>0.05). FBP1 protein expression level was significantly correlated with the expression levels of HIF-1α (P=0.005) and EPO (P=0.010), but not significantly correlated with the expression levels of HIF-2α (P=0.123) and CA9 (P=0.513) in ccRCC tissues. The current findings confirm the association between FBP1 and hypoxia-related gene expression, and may facilitate understanding of the mechanisms of ccRCC tumorigenesis.
Introduction
Clear cell renal cell carcinoma (ccRCC) is a cancer characterized by profound metabolic reprogramming and a "pseudo-hypoxic" state, usually driven by mutations in the VHL gene. This state leads to the accumulation of Hypoxia-Inducible Factors (HIFs), which trigger the expression of genes that help the tumor survive in low-oxygen environments. Fructose-1,6-bisphosphatase 1 (FBP1) is a well-known rate-limiting enzyme in gluconeogenesis. However, recent biochemical studies suggested that FBP1 also acts as a tumor suppressor by physically entering the nucleus and inhibiting HIF. This paper seeks to validate this relationship in a clinical setting by examining whether FBP1 levels correlate with hypoxia-related markers in patient tissue samples.
Methods
The researchers conducted a retrospective analysis of 123 patients who underwent surgery for ccRCC at the Peking University First Hospital. They utilized Tissue Microarrays (TMA) to organize tumor and adjacent healthy tissue samples for high-throughput analysis. Immunohistochemistry (IHC) was performed using specific antibodies for FBP1, HIF-1α, HIF-2α, erythropoietin (EPO), and carbonic anhydrase IX (CA9). Staining intensity was scored on a scale of 0 to 3 by two independent pathologists; scores of 0–1 were categorized as "low expression," while 2–3 were "high expression." Statistical correlations were determined using $\chi^2$ and Fisher’s exact tests.
Results
The study found that FBP1 expression is dramatically reduced in ccRCC compared to healthy kidney tissue, with 77.2% of tumor samples showing low expression versus only 8.1% in adjacent normal tissues ($P < 0.001$).
Statistical analysis of the protein expression levels revealed significant correlations between FBP1 and specific hypoxia-related factors. Specifically, low FBP1 expression was significantly associated with high expression of HIF-1α ($P = 0.005$) and EPO ($P = 0.010$).
Interestingly, no significant correlation was found between FBP1 and HIF-2α ($P = 0.123$) or CA9 ($P = 0.513$). Furthermore, clinicopathological factors such as age, gender, tumor stage, and Fuhrman grade did not differ significantly between the high and low FBP1 expression groups in this cohort.
Discussion
These findings reinforce the "moonlighting" regulatory role of FBP1 beyond its traditional metabolic function. The selective correlation with HIF-1α, but not HIF-2α, suggests that FBP1's inhibitory role is subunit-specific, primarily affecting metabolic homeostasis pathways rather than growth and angiogenesis drivers. The significant link with EPO is also noteworthy, as EPO can promote tumor progression.
Limitations of the study include a cohort predominantly composed of low-stage and low-grade tumors, which may explain the lack of correlation with clinical progression markers found in other studies. Future research should investigate the molecular mechanisms of FBP1 silencing in ccRCC and explore the therapeutic potential of restoring FBP1 to repress the hypoxic response in kidney cancer.
Summary updated